Baseline characteristics of patients with and without events are shown in (Table 1). During the follow-up period of 39.2 ± 22.6 months, 27 patients (4.8%) experienced adverse events, including death in 9 patients, ischemic stroke in 9, TIA in 6, pulmonary embolisms in 2, and peripheral embolism in 1. Three of the 27 patients experienced events within the blanking period after catheter ablation. Significant predictors of adverse events based on the univariate Cox regression analysis are shown in (Table 2). The CHADS2 and CHA2DS2-VASc scores remained independent predictors of adverse events in separate multivariate models (Tables 3, 4). Besides the CHADS2 and CHA2DS2-VASc scores, AF recurrence after multiple procedures was a significant predictor of adverse events. The event rate was higher in patients with recurrences than in patients without recurrences (9.6% vs. 2.8%, p = 0.001). When events were further divided into ischemic stroke/TIA, other embolic events, and death, the CHADS2 and CHA2DS2-VASc scores remained significant predictors. Hazard ratios of each increment of the CHADS2 scores to predict ischemic stroke/TIA, other embolic events, and death were 1.893 (95% confidence interval [CI]: 1.364 to 2.627, p < 0.001), 2.306 (95% CI: 1.116 to 4.764, p = 0.024), and 1.786 (95% CI: 1.159 to 2.754, p = 0.009), respectively. Similarly, hazard ratios of each increment of the CHA2DS2-VASc scores to predict ischemic stroke/TIA, other embolic events, and death were 1.694 (95% CI: 1.321 to 2.173, p < 0.001), 2.088 (95% CI: 1.1865 to 3.6789, p = 0.011), and 1.551 (95% CI: 1.108 to 2.171, p = 0.010), respectively. The usefulness of these 2 scoring systems in predicting strokes/TIAs was consistent in patients with and without recurrences.